Ernst Lengyel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1736472/publications.pdf

Version: 2024-02-01

176	21,219	17429 63	9854 141
papers	citations	h-index	g-index

183	183	183	28087
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes and Development, 2008, 22, 894-907.	2.7	2,007
2	Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine, 2011, 17, 1498-1503.	15.2	1,740
3	Ovarian Cancer Development and Metastasis. American Journal of Pathology, 2010, 177, 1053-1064.	1.9	1,312
4	Wholeâ€“genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	13.7	1,206
5	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	12.8	1,084
6	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	12.8	839
7	m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nature Cell Biology, 2018, 20, 1074-1083.	4.6	592
8	Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1533-1541.	1.2	578
9	Let-7 expression defines two differentiation stages of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11400-11405.	3.3	434
10	Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene, 2000, 19, 3013-3020.	2.6	348
11	CD95 promotes tumour growth. Nature, 2010, 465, 492-496.	13.7	339
12	Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene, 2018, 37, 2285-2301.	2.6	332
13	Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature, 2019, 569, 723-728.	13.7	330
14	Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via Î±5-Integrin, which Is a Therapeutic Target. Cancer Research, 2008, 68, 2329-2339.	0.4	325
15	Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences. Journal of Biological Chemistry, 1996, 271, 10672-10680.	1.6	323
16	MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer. Cancer Discovery, 2012, 2, 1100-1108.	7.7	314
17	The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. Journal of Clinical Investigation, 2008, 118, 1367-1379.	3.9	303
18	Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends in Cancer, 2018, 4, 374-384.	3.8	286

#	Article	IF	Citations
19	Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. Journal of Experimental Medicine, 2019, 216, 176-194.	4.2	278
20	Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1356-1365.	0.4	274
21	Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. International Journal of Cancer, 2007, 121, 1463-1472.	2.3	257
22	Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. Journal of Clinical Investigation, 2014, 124, 4614-4628.	3.9	247
23	c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion. Cancer Research, 2007, 67, 1670-1679.	0.4	239
24	Ligand-independent activation of c-Met by fibronectin and Î±5Î²1-integrin regulates ovarian cancer invasion and metastasis. Oncogene, 2011, 30, 1566-1576.	2.6	235
25	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International Journal of Cancer, 2005, 113, 678-682.	2.3	227
26	Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene, 1997, 14, 1481-1493.	2.6	226
27	Let-7 Prevents Early Cancer Progression by Suppressing Expression of the Embryonic Gene HMGA2. Cell Cycle, 2007, 6, 2585-2590.	1.3	217
28	Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metabolism, 2016, 24, 728-739.	7.2	192
29	Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metabolism, 2019, 29, 141-155.e9.	7.2	192
30	Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Molecular Cancer Research, 2017, 15, 78-92.	1.5	178
31	Epithelial ovarian cancer experimental models. Oncogene, 2014, 33, 3619-3633.	2.6	170
32	Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nature Communications, 2015, 6, 6220.	5.8	168
33	Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discovery, 2016, 6, 1342-1351.	7.7	168
34	Deep Visual Proteomics defines single-cell identity and heterogeneity. Nature Biotechnology, 2022, 40, 1231-1240.	9.4	160
35	Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene, 2004, 23, 9369-9380.	2.6	157
36	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstetrics and Gynecology, 2021, 137, 108-121.	1.2	150

#	Article	IF	Citations
37	Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity. Obstetrics and Gynecology, 2012, 119, 61-67.	1.2	149
38	A phase II, single-arm study of the anti-Î±5Î²1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology, 2011, 121, 273-279.	0.6	144
39	Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Research, 2020, 80, 1748-1761.	0.4	139
40	Letâ€7 modulates acquired resistance of ovarian cancer to Taxanes via IMPâ€1â€mediated stabilization of multidrug resistance 1. International Journal of Cancer, 2012, 130, 1787-1797.	2.3	131
41	Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell, 2018, 175, 159-170.e16.	13.5	127
42	Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell, 2021, 184, 3163-3177.e21.	13.5	119
43	MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle, 2009, 8, 683-688.	1.3	118
44	A streamlined mass spectrometryâ€"based proteomics workflow for largeâ€scale FFPE tissue analysis. Journal of Pathology, 2020, 251, 100-112.	2.1	109
45	HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. Journal of Clinical Investigation, 2012, 122, 3603-3617.	3.9	108
46	Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. American Journal of Obstetrics and Gynecology, 2015, 212, 479.e1-479.e10.	0.7	106
47	The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis and Proteolysis, 2000, 14, 114-132.	1.1	102
48	miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrin Î±5 Expression. American Journal of Pathology, 2013, 182, 1876-1889.	1.9	98
49	Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis. Clinical Cancer Research, 2011, 17, 4042-4051.	3.2	97
50	Expression of Latent Matrix Metalloproteinase 9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer. Gynecologic Oncology, 2001, 82, 291-298.	0.6	96
51	Who are the long-term survivors of high grade serous ovarian cancer?. Gynecologic Oncology, 2018, 148, 204-212.	0.6	87
52	Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment. Clinical Cancer Research, 2015, 21, 680-686.	3.2	83
53	Organotypic Models of Metastasis: A Three-dimensional Culture Mimicking the Human Peritoneum and Omentum for the Study of the Early Steps of Ovarian Cancer Metastasis. Cancer Treatment and Research, 2009, 149, 335-351.	0.2	82
54	Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Communications Biology, 2019, 2, 386.	2.0	81

#	Article	IF	Citations
55	Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor. Journal of Biological Chemistry, 1999, 274, 16377-16386.	1.6	80
56	An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis. Neoplasia, 2010, 12, 1-10.	2.3	70
57	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptorâ€“Engineered T Cells for Ovarian Cancer. Clinical Cancer Research, 2018, 24, 5357-5367.	3.2	70
58	Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene, 1997, 14, 2563-2573.	2.6	69
59	Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis. Clinical Cancer Research, 2011, 17, 459-471.	3.2	69
60	Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene. Journal of Biological Chemistry, 1996, 271, 23176-23184.	1.6	68
61	Î²3-Integrin Expression on Tumor Cells Inhibits Tumor Progression, Reduces Metastasis, and Is Associated with a Favorable Prognosis in Patients with Ovarian Cancer. American Journal of Pathology, 2009, 175, 2184-2196.	1.9	68
62	Thrombin Induces Tumor Invasion through the Induction and Association of Matrix Metalloproteinase-9 and Î²1-Integrin on the Cell Surface. Journal of Biological Chemistry, 2008, 283, 2822-2834.	1.6	66
63	The First Line of Intra-abdominal Metastatic Attack: Breaching the Mesothelial Cell Layer. Cancer Discovery, 2011, 1, 100-102.	7.7	66
64	In vitro modulation of human melanoma cell invasion and proliferation by all-frans-retinoic acid. Melanoma Research, 1998, 8, 211-219.	0.6	65
65	Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras. Journal of Biological Chemistry, 1995, 270, 23007-23012.	1.6	63
66	Tyrosine Kinase Mutations in Human Cancer. Current Molecular Medicine, 2007, 7, 77-84.	0.6	63
67	Old drug, new trick: Repurposing metformin for gynecologic cancers?. Gynecologic Oncology, 2014, 135, 614-621.	0.6	63
68	The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget, 2015, 6, 11342-11356.	0.8	62
69	Integrin Î±vÎ²3/Vitronectin Interaction Affects Expression of the Urokinase System in Human Ovarian Cancer Cells. Journal of Biological Chemistry, 2001, 276, 26340-26348.	1.6	59
70	Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2015, 138, 656-662.	0.6	57
71	Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Molecular Cancer Therapeutics, 2016, 15, 2282-2293.	1.9	57
72	Expression of the Homeobox Gene HOXA9 in Ovarian Cancer Induces Peritoneal Macrophages to Acquire an M2 Tumor-Promoting Phenotype. American Journal of Pathology, 2014, 184, 271-281.	1.9	54

#	Article	IF	Citations
73	SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Molecular Cancer Research, 2019, 17, 870-881.	1.5	50
74	Î² 3 A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through a PEA3/ets Transcriptional Silencing Element in the u-PAR Promoter. Molecular and Cellular Biology, 2001, 21, 2118-2132.	1.1	47
75	Up-Regulation of Î±5-Integrin by E-Cadherin Loss in Hypoxia and Its Key Role in the Migration of Extravillous Trophoblast Cells during Early Implantation. Endocrinology, 2009, 150, 4306-4315.	1.4	47
76	Unsaturated Fatty Acids Maintain Cancer Cell Stemness. Cell Stem Cell, 2017, 20, 291-292.	5.2	47
77	Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. Journal of Cellular Biochemistry, 1996, 61, 430-443.	1.2	46
78	RADAR: differential analysis of MeRIP-seq data with a random effect model. Genome Biology, 2019, 20, 294.	3.8	46
79	PDGFR-Î± as a potential therapeutic target in uterine sarcomas. Gynecologic Oncology, 2007, 104, 524-528.	0.6	45
80	Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology, 2007, 51, 54-62.	1.6	44
81	Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecologic Oncology, 2008, 111, 173-178.	0.6	43
82	The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertility and Sterility, 2010, 94, 1212-1217.	0.5	40
83	Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis. PLoS ONE, 2014, 9, e104521.	1.1	39
84	A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 57-67.	0.6	38
85	UVB Increases Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression1. Journal of Investigative Dermatology, 1999, 113, 69-76.	0.3	37
86	A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials, 2019, 190-191, 63-75.	5.7	37
87	Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. Journal of Women's Health, 2021, 30, 502-513.	1.5	36
88	Three-dimensional modeling of ovarian cancer. Advanced Drug Delivery Reviews, 2014, 79-80, 184-192.	6.6	35
89	Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget, 2015, 6, 23548-23560.	0.8	35
90	Urokinase Plasminogen Activator Systemâ€“Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapy. Molecular Cancer Therapeutics, 2013, 12, 2628-2639.	1.9	34

#	Article	IF	Citations
91	New Roles for Glycogen in Tumor Progression. Trends in Cancer, 2019, 5, 396-399.	3.8	34
92	Src Induces Urokinase Receptor Gene Expression and Invasion/Intravasation via Activator Protein-1/p-c-Jun in Colorectal Cancer. Molecular Cancer Research, 2007, 5, 485-496.	1.5	33
93	An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nature Communications, 2017, 8, 1775.	5.8	33
94	Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway Implications for atherogenesis. Cardiovascular Research, 2001, 49, 189-199.	1.8	32
95	Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2. Endocrinology, 2001, 142, 3663-3672.	1.4	32
96	Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget, 2020, 11, 3621-3632.	0.8	29
97	Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2Î±-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers. Clinical Cancer Research, 2005, 11, 8538-8548.	3.2	28
98	High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecologic Oncology, 2017, 146, 153-160.	0.6	28
99	Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecologic Oncology, 2015, 137, 485-489.	0.6	27
100	Stimulation of urokinase expression by TNF-Î± requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochimica Et Biophysica Acta - Molecular Cell Research, 1995, 1268, 65-72.	1.9	26
101	FOXL2 and SOX9 Distinguish the Lineage of the Sex Cordâ€“Stromal Cells in Gonadoblastomas. Pediatric and Developmental Pathology, 2011, 14, 391-395.	0.5	26
102	A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discovery, 2017, 22, 494-506.	1.4	26
103	Mesothelial Cell HIF1Î± Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Reports, 2019, 29, 4086-4098.e6.	2.9	26
104	Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecologic Oncology, 2019, 153, 405-415.	0.6	25
105	Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Molecular Cancer Therapeutics, 2020, 19, 52-62.	1.9	24
106	The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecologic Oncology, 2019, 152, 228-234.	0.6	23
107	Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. Obstetrics and Gynecology, 2000, 96, 582-587.	1.2	21
108	The MÃ¼llerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelialâ€“stromal interactions. Molecular and Cellular Endocrinology, 2010, 317, 112-119.	1.6	21

#	Article	IF	Citations
109	The Natural Product Î²-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis. Cancers, 2021, 13, 3931.	1.7	20
110	Resilience: a mediator of the negative effects of pandemic-related stress on womenâ€™s mental health in the USA. Archives of Women's Mental Health, 2022, 25, 137-146.	1.2	20
111	Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer Research, 2022, 82, 169-176.	0.4	19
112	Cytological diagnosis of zosteriform skin metastases in undiagnosed breast carcinoma. British Journal of Dermatology, 1996, 135, 502-503.	1.4	18
113	Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Human Molecular Genetics, 2009, 18, 3632-3644.	1.4	18
114	Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecologic Oncology, 2012, 127, 316-320.	0.6	18
115	Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prevention Research, 2017, 10, 255-266.	0.7	18
116	Role of Î²3-endonexin in the regulation of NF-ÎºB-dependent expression of urokinase-type plasminogen activator receptor. Journal of Cell Science, 2002, 115, 3879-3888.	1.2	17
117	The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends in Cancer, 2018, 4, 517-519.	3.8	17
118	Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecologic Oncology, 2008, 111, 537-539.	0.6	16
119	Prolactin Receptorâ€“Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Research, 2017, 77, 1684-1696.	0.4	16
120	Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Scientific Reports, 2019, 9, 5195.	1.6	16
121	Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. Journal of Visualized Experiments, 2015, , e53541.	0.2	14
122	The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Research, 2021, 81, 3985-4000.	0.4	14
123	Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice. Cancer Prevention Research, 2009, 2, 792-799.	0.7	13
124	Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecologic Oncology, 2013, 129, 120-123.	0.6	13
125	Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer. JCO Oncology Practice, 2022, 18, e948-e957.	1.4	12
126	Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecologic Oncology, 2004, 94, 204-207.	0.6	11

#	Article	IF	Citations
127	The effects of 17Î²-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecologic Oncology, 2012, 124, 134-141.	0.6	11
128	Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21493-21500.	3.3	11
129	The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecologic Oncology, 2011, 121, 218-223.	0.6	9
130	The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. Cancers, 2021, 13, 3136.	1.7	9
131	Keratin expression reveals mosaic differentiation in vaginal epithelium. American Journal of Obstetrics and Gynecology, 1993, 169, 1603-1607.	0.7	7
132	Ras Regulation of urokinase-type plasminogen activator. Methods in Enzymology, 2001, 333, 105-116.	0.4	7
133	Physiology of cervical ripening and dilatation. Der Gynakologe, 2001, 34, 708-714.	1.0	7
134	JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation. Transplantation Proceedings, 2001, 33, 931-932.	0.3	6
135	Transverse Transperineal Repair of a Pessary-induced Mid-rectovaginal Fistula. Journal of Pelvic Medicine & Surgery, 2008, 14, 199-201.	0.1	6
136	Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?. JAMA Network Open, 2020, 3, e2014184.	2.8	6
137	Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecologic Oncology, 2021, 163, 130-133.	0.6	5
138	Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. Gynecologic Oncology, 2012, 127, S5-S6.	0.6	3
139	High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecologic Oncology Reports, 2022, 41, 100987.	0.3	3
140	Downregulation of a Mitogen-Activated Protein Kinase Signaling Pathway in the Placentas of Women With Preeclampsia. Obstetrics and Gynecology, 2000, 96, 582-587.	1.2	2
141	Isolation and characterization of Rac1 pseudogenes (Ï^1Rac1â€“Ï^4Rac1) in the human genome. Gene, 2004, 341, 189-197.	1.0	2
142	RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. , 2001, 39, 299-306.		1
143	Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice. Obstetrical and Gynecological Survey, 2010, 65, 35-37.	0.2	1
144	Abstract 1481: microRNA mediated reprograming of fibroblasts into cancer associated fibroblasts in ovarian cancer. , 2012, , .		1

#	Article	IF	Citations
145	Ovarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome. Journal of Clinical Oncology, 2008, 26, 16531-16531.	0.8	1
146	Metabolic reprogramming of the stromal epigenome in ovarian cancer metastasis. FASEB Journal, 2019, 33, lb240.	0.2	1
147	UVB induces the transcription of urokinase receptor in A431 cells. Journal of Dermatological Science, 1998, 16, S225.	1.0	0
148	P3. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2Î±-related factor binding to different regions of the urokinase receptor (u-PAR) gene in resected colorectal cancers. European Journal of Cancer, Supplement, 2006, 4, 28.	2.2	0
149	P4. Tumor suppressor Pdcd4 inhibits invasion and regulates urokinase-receptor (u-PAR) gene expression via Sp-transcription factors. European Journal of Cancer, Supplement, 2006, 4, 28.	2.2	0
150	A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer. Scientific World Journal, The, 2008, 8, 905-908.	0.8	0
151	Locoregional Failure In High-risk Endometrial Cancer And The Role Of Whole Pelvis External Beam RT. International Journal of Radiation Oncology Biology Physics, 2011, 81, S475-S476.	0.4	0
152	Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity. Obstetrical and Gynecological Survey, 2012, 67, 96-97.	0.2	0
153	Metformin: A novel agent for ovarian cancer prevention and adjuvant treatment. Gynecologic Oncology, 2012, 125, S100.	0.6	0
154	Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. Gynecologic Oncology, 2012, 125, S151-S152.	0.6	0
155	Regulation of ovarian cancer metastatic colonization by MIR-193B. Gynecologic Oncology, 2013, 131, 259-260.	0.6	0
156	Identifying the microrna expression signature associated with chemoresistance in ovarian cancer. Gynecologic Oncology, 2013, 131, 256-257.	0.6	0
157	Old Drug, New Trick. Obstetrical and Gynecological Survey, 2015, 70, 91-92.	0.2	0
158	Healthy food for trainees: a call to action. Postgraduate Medical Journal, 2021, 97, 740-741.	0.9	0
159	Abstract 2331: One of the first steps of metastasis is remodeling of the extracellular matrix microenvironment. , 2010, , .		0
160	Abstract LB-341: CD95/FAS promotes tumorigenesis. , 2010, , .		0
161	Abstract A103: The effect of 17Î²-estradiol on ovarian carcinogenesis in vitro and in a genetic mouse model. , 2010, , .		0
162	Abstract 1544: Identification of microRNA which regulates peritoneal dissemination of ovarian cancer. , 2011, , .		0

#	Article	IF	Citations
163	Abstract 2885: Urokinase plasminogen activator system targeted delivery of arsenic trioxide loaded nanobins as a novel ovarian cancer therapeutic. , 2012, , .		0
164	Abstract 5185: Ovarian cancer cells induce fibronectin production in the peritoneal microenvironment through a TGFÎ²RI-dependent mechanism which promotes the early steps of metastasis. , 2012, , .		0
165	Abstract 48: Activation of c-Met receptor signaling by carcinoma-associated fibroblasts in the tumor microenvironment. , 2012, , .		0
166	Abstract IA30: Metabolic symbiosis: The contribution of adipocytes to visceral metastasis. , 2013, , .		0
167	Abstract 2611: The developmental patterning geneHOXA9promotes ovarian cancer growth via paracrine effects on mesenchymal stem cells and peritoneal fibroblasts.. , 2013, , .		0
168	Abstract 1870: Omental adipocytes promote overexpression of CD36 in ovarian cancer cells and enhance tumorigenicity.. , 2013, , .		0
169	Abstract B32: The role of the glucocorticoid receptor (GR) in inhibiting chemotherapy-induced apoptosis in high-grade serous ovarian carcinoma (HGS-OvCa). , 2013, , .		0
170	Abstract PR11: Ovarian cancer cells activate the mesothelium in the peritoneal microenvironment promoting fibronectin production and the early steps of metastasis. , 2013, , .		0
171	Abstract POSTER-BIOL-1305: Lovastatin decreases macrophage IL-6 and CXCL1 production in an ovarian tam-like model reducing ovarian cancer cell invasion. , 2015, , .		0
172	Abstract POSTER-CTRL-1217: Human placental lactogen-functionalized bimodal imaging probe for human ovarian cancer detection. , 2015, , .		0
173	Abstract POSTER-THER-1440: Targeted delivery of doxorubicin loaded nanobins to ovarian cancer cells through the urokinase plasminogen activator system. , 2015, , .		0
174	Abstract POSTER-TECH-1123: Advancing metformin as therapeutic for ovarian cancer: metabolomic profiling of mouse ovarian tumors identifies metformin-induced global metabolic changes. , 2015, , .		0
175	Abstract A68: Sphingosine kinase 1 as a mediator and predictor of metformin's protective effect in ovarian cancer.. , 2016, , .		0
176	Abstract B39: Identification and targeting mediators of chemoresistance using the patient-derived xenograft model of ovarian cancer. , 2016, , .		0